Table 3.
Survived (n) | Expired (n) | HR (95% CI)* | HR (95% CI)† | |
---|---|---|---|---|
All patients (n = 580) | ||||
Troponin I (ng/mL) | ||||
< 0.06 | 234 | 167 | 1.0 | 1.0 |
0.06 - | 28 | 59 | 1.29 (0.95–1.76) | 1.20 (0.89–1.62) |
0.21 - | 31 | 61 | 1.39 (1.04–1.88) | 1.39 (1.01–1.89) |
p-trend | 0.0167 | 0.0307 | ||
Age ≤ 65 y (n = 366) | ||||
Troponin I (ng/mL) | ||||
< 0.06 | 191 | 66 | 1.0 | 1.0 |
0.06 - | 19 | 29 | 2.54 (1.63–3.96) | 2.18 (1.40–3.41) |
0.21 - | 17 | 44 | 2.28 (1.53–3.40) | 2.05 (1.36–3.09) |
p-trend | < 0.0001 | < 0.0001 | ||
Age > 65 y (n = 214) | ||||
Troponin I (ng/mL) | ||||
< 0.06 | 43 | 101 | 1.0 | 1.0 |
0.06 - | 9 | 30 | 0.76 (0.49–1.18) | 0.74 (0.49–1.12) |
0.21 - | 14 | 17 | 0.67 (0.40–1.13) | 0.77 (0.43–1.38) |
p-trend | 0.0826 | 0.1688 | ||
p-interaction | < 0.0001 | 0.0090 |
Analysis of peak cTnI value as a single exposure; adjusted for age, gender, injury type (including MVC, fall, other blunt trauma, penetrating injuries, and other injury types), ISS, admission GCS score, surgical intervention, and preexisting cardiac diseases.
Analysis using repeated measures of cTnI levels as time-dependent exposures; adjusted for all potential cofounders mentioned above.